Aptevo investors back directors, pay and stock plan

Aptevo Therapeutics Inc. (APVO) reported the results of its 2026 Annual Meeting of Stockholders held on August 21, 2026.

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. (APVO) reported the results of its 2026 Annual Meeting of Stockholders held on August 21, 2026. A quorum was present and four proposals were voted on.

Stockholders elected two directors, Zsolt Harsanyi, Ph.D. and Barbara Lopez Kunz, to the board to serve until the 2029 Annual Meeting and until their successors are elected and qualified. Baker Tilly US, LLP was approved as independent registered public accounting firm for the year ending December 31, 2026. Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers for 2025, and also approved Aptevo’s Fourth Amended and Restated 2018 Stock Incentive Plan.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Zsolt Harsanyi, Ph.D.: 216,997 Votes for Barbara Lopez Kunz: 211,050 Votes for auditor ratification: 606,661 +4 more

7 metrics

Votes for Zsolt Harsanyi, Ph.D. 216,997 Election as director to serve until the 2029 Annual Meeting

Votes for Barbara Lopez Kunz 211,050 Election as director to serve until the 2029 Annual Meeting

Votes for auditor ratification 606,661 For ratification of Baker Tilly US, LLP as auditor for 2026

Votes for 2025 executive compensation (advisory) 165,615 For the non-binding advisory vote on named executive officer compensation

Votes for Fourth Amended and Restated 2018 Stock Incentive Plan 166,484 For approval of the stock incentive plan

Broker non-votes on executive compensation proposal 402,427 Broker non-votes for the 2025 executive compensation advisory proposal

Broker non-votes on stock incentive plan proposal 402,427 Broker non-votes for the Fourth Amended and Restated 2018 Stock Incentive Plan proposal

Key Terms

broker non-votes, independent registered public accounting firm, non-binding advisory vote, Fourth Amended and Restated 2018 Stock Incentive Plan

4 terms

broker non-votes financial

"FOR | AGAINST | ABSTAIN | BROKER NON-VOTES 165,615 |"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"The appointment of Baker Tilly US, LLP to serve as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

non-binding advisory vote financial

"The non-binding advisory vote on the compensation paid to our named executive officers"

A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.

Fourth Amended and Restated 2018 Stock Incentive Plan financial

"The Aptevo Therapeutics Inc. Fourth Amended and Restated 2018 Stock Incentive Plan was approved"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did APVO stockholders decide at the 2026 Annual Meeting?

Stockholders elected two directors to serve until 2029, ratified Baker Tilly US, LLP as independent auditor for 2026, approved on an advisory basis 2025 executive compensation, and approved the Fourth Amended and Restated 2018 Stock Incentive Plan.

Who was elected to Aptevo Therapeutics Inc. (APVO)’s board in 2026?

Zsolt Harsanyi, Ph.D. and Barbara Lopez Kunz were elected as directors. They will serve until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.

Was the auditor ratified by APVO stockholders for 2026?

Yes. Stockholders approved Baker Tilly US, LLP as Aptevo’s independent registered public accounting firm for the year ending December 31, 2026, with 606,661 votes for, 28,847 against, and 1,370 abstentions.

How did APVO stockholders vote on 2025 executive compensation?

The advisory vote on 2025 executive compensation was approved, receiving 165,615 votes for, 24,031 against, and 44,805 abstentions, with 402,427 broker non-votes.

Did APVO’s Fourth Amended and Restated 2018 Stock Incentive Plan get approved?

Yes. The Fourth Amended and Restated 2018 Stock Incentive Plan was approved with 166,484 votes for, 64,248 against, and 3,719 abstentions, and 402,427 broker non-votes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2026 - 04:05 PM EDT Learn about SEC filing dates

0001671584false00016715842026-08-212026-08-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2026

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37746	81-1567056
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2401 4th Avenue Suite 1050
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		APVO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 21, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on July 31, 2026 (the “Proxy Statement”). The final voting results with respect to each of the proposals acted upon at the 2026 Annual Meeting are set forth below.

Proposal 1: Election of Directors

The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes:

	FOR	WITHHELD	BROKER NON-VOTES
Zsolt Harsanyi, Ph.D.	216,997	17,454	402,427
Barbara Lopez Kunz	211,050	23,401	402,427

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2026

The appointment of Baker Tilly US, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved based on the following votes:

FOR		AGAINST		ABSTAIN		BROKER NON-VOTES
606,661		28,847		1,370		0

Proposal 3: Advisory Vote on Company's 2025 Executive Compensation

The non-binding advisory vote on the compensation paid to our named executive officers was approved based on the following votes:

FOR		AGAINST		ABSTAIN		BROKER NON-VOTES
165,615		24,031		44,805		402,427

Proposal 4: Approval of the Company's Fourth Amended and Restated 2018 Stock Incentive Plan

The Aptevo Therapeutics Inc. Fourth Amended and Restated 2018 Stock Incentive Plan was approved based on the following votes:

FOR		AGAINST		ABSTAIN		BROKER NON-VOTES
166,484		64,248		3,719		402,427

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APTEVO THERAPEUTICS INC.
Date:	August 21, 2026	By:	/s/ Daphne Taylor
			Daphne Taylor Senior Vice President and Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB